

Certificate of Analysis

p38 α /SAPK2a (T106M) , active (Recombinant enzyme expressed in *E. coli* cells)

Item # 14-687, 14-687-K, 14-687M

Parent Lot # 1590325

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged, recombinant, human, full-length p38 α /SAPK2a containing the mutation T106M. Expressed in *E. coli* cells. Purified using glutathione-agarose. Activated using DD-MKK6 (cat# 14-537) and repurified using glutathione- agarose. Purity 92.9% by SDS-PAGE and Coomassie blue staining. MW = 67.7kDa.

Specific Activity (Parent lot# 1590325): 97U/mg, where one unit of p38 α /SAPK2a (T106M) activity is defined as 1nmol phosphate incorporated into 0.33mg/ml myelin basic protein (MBP) per minute at 30°C with a final ATP concentration of 100 μ M.


Formulation: 1.879mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 50% glycerol, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Liquid solution at -20°C.

Storage and Stability: On receipt of material store at -20°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 15–41ng of this lot of enzyme phosphorylated 0.33mg/ml myelin basic protein (MBP) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as p38 α /SAPK2a (T106M) with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Myelin Basic Protein (MBP):** Use at a final assay concentration of 0.33mg/ml. Make up a 3.3mg/ml stock. Use 2.5µl of stock per assay point.
3. **p38α/SAPK2a (T106M), active:** Dilute with 20mM MOPS/NaOH pH 7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1 mg/ml BSA. Use 15–41ng per assay point.
4. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **myelin basic protein (MBP)**.
3. Add **2.5µl (15–41ng) p38α/SAPK2a (T106M), active**.
4. Add 5µl of dH₂O.
5. Add 10µl of diluted [γ-³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

p38α/SAPK2a (T106M) Sequence Information

<u>Protein</u>	Human p38α/SAPK2a (T106M)
<u>Tags</u>	N-terminal GST
<u>Native sequence</u>	M227 of the recombinant protein is equivalent to M1 of human p38α/SAPK2a
<u>Accession number</u>	GenBank L35264. The p38α/SAPK2a recombinant protein contains the amino acid substitution T106M with respect to GenBank L35764. This mutation confers resistance to SB203580.

Recombinant p38α/SAPK2a (T106M) amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSM  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121  DFSLKLP  EML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181  KRIEAI  PQID  KYLKSSKYIA  WPLQGWQATF  GGDHPPKSD  LVPRGSMSQE  RPTFYRQELN
241  KTIWEV  PERY  QNLSPVGS  GA  YGSVCAAFDT  KTGLRVAVKK  LSRPFQSI  IH  AKRTYRELRL
301  LKHKH  ENVI  GLLDVFT  PAR  SLEEFNDVYL  VMHLMGADLN  NIVKCQK  LTD  DHVQFLIYQI
361  LRGLK  YIHS  A  DIIHRDLK  PS  NLAVNEDCEL  KILDFGLARH  TDDEMTG  YVA  TRWYRAPEIM
421  LNMWH  YNQT  V  DIWSVGC  IMA  ELLTGRTLF  P  GTDHIDQL  KL  ILRLVGT  PGA  ELLKKISSES
481  ARNYI  QSLT  Q  MPKMN  FANVF  IGANPLAV  DL  LEKMLV  LDS  KRITAAQ  ALA  HAYFAQYHDP
541  DDEPV  ADPYD  QSFESR  DLLI  DEWKSL  TYDE  VISFV  PPPLD  QEEMES

```

Recombinant p38α/SAPK2a (T106M) nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aagggccttg  tgcaaccac  tcgacttctt
61  ttggaatata  ttgaagaaaa  atatgaagag  catttgatg  agcgcgatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttcca  atcttcctta  ttatatgtat
181  ggtgatgtta  aattaacaca  gtctatggcc  atcatacgtt  atatagctga  caagcacaac
241  atgttggggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcgggtttg
301  gatattagat  acgggtgttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acataattaa  atggtgatca  tgtaacccat  cctgacttca  tgttgatga  cgctcttgat
481  gttgttttat  acatggaccc  aatgtgcctg  gatgcttcc  caaaattagt  ttgttttaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggttccgc  gtggatccat  gtctcaggag  aggcccaagt  tctaccggca  ggagctgaac
721  aagacaatct  gggaggtgcc  cgagcgttac  cagaacctgt  ctccagtggt  ctctggcgcc
781  tatggctctg  tgtgtgctgc  ttttgacaca  aagacggggg  tacgtgtggc  agtgaagaag
841  ctctccagac  catttcagtc  catcattcat  gcgaaaagaa  cctacagaga  actgcggtta
901  cttaaacata  tgaaacatga  aaatgtgatt  ggtctgttgg  acgtttttac  acctgcaagg
961  tctctggagg  aattcaatga  tgtgtatctg  gtgatgcata  tcatgggggc  agatctgaac
1021  aacattgtga  aatgtcagaa  gcttacagat  gaccatgttc  agttccttat  ctaccaaatt
1081  ctccgagggtc  taaagtatat  acattcagct  gacataattc  acagggacct  aaaacctagt
1141  aatctagctg  tgaatgaaga  ctgtgagctg  aagattctgg  attttggact  ggctcggcac
1201  acagatgatg  aatgacagg  ctacgtggcc  actaggtggt  acagggctcc  tgagatcatg

```

Certificate of Analysis

```
1261 ctgaactgga tgcattacaa ccagacagtt gatatttggg cagtgggatg cataatggcc
1321 gagctgttga ctggaagaac attgtttcct ggtacagacc atattgatca gttgaagctc
1381 attttaagac tcgttggaac cccaggggct gagcttttga agaaaatctc ctcagagtct
1441 gcaagaaact atattcagtc tttgactcag atgccgaaga tgaactttgc gaatgtattt
1501 attggtgcca atcccctggc tgtcgacttg ctggagaaga tgcttgattt ggactcagat
1561 aagagaatta cagcggccca agcccttgca catgcctact ttgctcagta ccacgatcct
1621 gatgatgaac cagtggccga tccttatgat cagtcctttg aaagcagga cctccttata
1681 gatgagtgga aaagcctgac ctatgatgaa gtcacacagct ttgtgccacc accccttgac
1741 caagaagaga tggagtcttg a
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.